• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Verana Research Network set sights on better access to clinical care


Marc Berger, Chief Operating Officer at Verana Health, highlights what a new initiative with the American Academy of Ophthalmology IRIS Registry will mean for patients and physicians.

Video transcript

Note: This transcript has been lightly edited for clarity.

Marc Berger: I'm Marc Berger, Chief Operating Officer of Verana Health. In collaboration with the American Academy of Ophthalmology, the Verana Research Network is going to be leveraging the IRIS Registry [Intelligent Research in Sight) in a new initiative to advance clinical trials, clinical trial participation and advancing clinical care.

For patients, we expect to be able to get better access to clinical care, to get access to trials that otherwise they may not have been able to get access to, as well as drive new innovations in care and treatment patterns.

For physicians, they're going to get to see access. They're going to be able to do better care for their patients. They can get better access to other clinical trials that they may not have seen before. Verana has a unique relationship with its sponsors, with the life science partners who can bring these clinical trials to the practices, who can then serve these patients with better care and better treatments through the advantages of getting access to the clinical trials.

We're rolling this out right now. We already have a group of academic medical centers and practices who are participating in this research network, who are actively getting access to this data, access to these trials, and identifying potential patients and potential sites that can participate in these trials.

I think the success is going to be the number of trials that we're able to bring to the AAO Registry participants, the new treatments that we're seeing as a result of these trials, and the care patterns that come as a result of this new research.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.